Date/Time: February 19th 2024, 12PM ET
Total duration: 90 minutes

Ways to watch

About this course

This program is supported by an independent education grant from ITF Therapeutics. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

Join us for a live online course presented by leading expert Dr. Martina Sandonà and with insights from Muscular Dystrophy Association. Delve into the latest advancements in Duchenne Muscular Dystrophy (DMD) and gain insights into the mechanisms of action of emerging therapies, such as HDAC inhibitors, and their potential impact on DMD patient outcomes.

Accreditation: 1.5 AMA PRA Category 1 Credits™ will be available for this education

Learning objectives:

1. Implement the Latest Data on Emerging DMD Therapies Such as HDAC Inhibitors:

• Evaluate the clinical trial data regarding new therapies such as HDAC Inhibitors, including the efficacy data on delaying key disease milestones like ambulation loss and functional decline.
• Incorporate the latest data into individualized treatment plans, balancing risks, benefits, and patient-specific factors.
• Review and adapt practice protocols to ensure timely and evidence-based initiation of advanced therapies beyondrelying solely on corticosteroids.

2. Enhance patient outcomes by optimizing care through a comprehensive understanding of the mechanism of action of HDAC inhibitors and their therapeutic applications:

• Analyze the mechanisms behind emerging therapies such as HDAC inhibitors, focusing on how they impact muscle regeneration, fibrosis, and inflammation.
• Apply this understanding of the mechanisms to improve decision-making in DMD treatment, selecting therapies that best match each patientʼs disease stage and pathology.
• Integrate this understanding into long-term management strategies, ensuring therapies are aligned with the evolving needs of patients.

Who is this for

This session is designed for healthcare professionals involved in the care of DMD patients, including:

• Pediatricians
• Neurologists
• Neuromuscular specialists
• Pediatric neurologists
• Geneticists
• Primary care physicians

Presented by

Martina Sandonà

Dr. Martina Sandonà is a postdoctoral researcher Università Cattolica del Sacro Cuore, Italy. Her research focuses on the role of post-translational modifications in muscular dystrophies, particularly the therapeutic potential of HDAC inhibitors. With a strong academic background, including a Master's degree in Chemistry and a PhD in Morphogenesis and Tissue Homeostasis, Dr. Sandona brings a wealth of knowledge and expertise to her work.

With address from the Muscular Dystrophy Association

Continuing Education Information

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty

Martina Sandona & Jessica Hubbard

Disclosures

Martina Sandonà has been the Principal Investigator for AFM-Telethon and an Inventor for Exofix Sr. She has no unapproved product related discussions to disclose.

Jessica Hubbard has no relevant financial relationships with ineligible companies to disclose and no unapproved product related discussions to disclose.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physician Assistants

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.